Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SYRE

Spyre Therapeutics Inc

Sep 12 • 04:00PM ET

15.65

-0.55 -3.40 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA BMY PFE LLY NVS

| Held by: VTI IWM XBI VXF IBB IWO VTWO SCHA IWN VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.05	Insider Own	15.51%	Shs Outstand	60.74M	Perf Week	-7.94%
Market Cap	945.26M	Forward P/E	-	EPS next Y	-3.27	Insider Trans	-0.20%	Shs Float	51.03M	Perf Month	-10.06%
Enterprise Value	418.68M	PEG	-	EPS next Q	-0.77	Inst Own	99.45%	Short Float	27.61%	Perf Quarter	-11.63%
Income	-170.19M	P/S	-	EPS this Y	10.06%	Inst Trans	2.92%	Short Ratio	25.47	Perf Half Y	-13.20%
Sales	0.00M	P/B	2.09	EPS next Y	-14.49%	ROA	-34.91%	Short Interest	14.09M	Perf YTD	-32.77%
Book/sh	7.50	P/C	1.80	EPS next 5Y	-2.73%	ROE	-41.00%	52W High	40.26 -61.13%	Perf Year	-44.48%
Cash/sh	8.72	P/FCF	-	EPS past 3/5Y	49.72% 44.65%	ROIC	-37.34%	52W Low	10.91 43.45%	Perf 3Y	25.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.00% 4.65%	Perf 5Y	-91.42%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-429.68%	Oper. Margin	-	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.49	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	40.69	Recom	1.23
Dividend Gr. 3/5Y	- -	Current Ratio	6.49	EPS Q/Q	-2.46%	SMA20	-6.10%	Beta	2.92	Target Price	53.90
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.08%	Rel Volume	0.78	Prev Close	16.20
Employees	65	LT Debt/Eq	0.00	Earnings	Aug 05 AMC	SMA200	-15.05%	Avg Volume	553.08K	Price	15.65
IPO	Apr 07, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.98% -	Trades		Volume	431,161	Change	-3.40%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-25	Initiated	Leerink Partners	Outperform	$45
Mar-18-25	Initiated	Wolfe Research	Outperform	$27
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

Aug-05-25 04:17PM	Spyre Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.39%
04:02PM	Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-25 04:41PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jul-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jun-17-25 07:30AM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts (PR Newswire) -11.64%
04:05PM	Loading…
Jun-16-25 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 (PR Newswire)
Jun-06-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
May-30-25 09:55AM	Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know (Zacks)
May-28-25 08:30AM	Spyre Therapeutics to Participate in Upcoming June Investor Conferences (PR Newswire)
May-13-25 09:55AM	How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% (Zacks)
May-08-25 04:05PM	Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +9.64%
May-05-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 (PR Newswire) -6.75%
May-02-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-04-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -8.58%
Mar-27-25 04:05PM	Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody (PR Newswire)
04:40PM	Loading…
Mar-07-25 04:40PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Feb-27-25 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
Feb-25-25 08:00AM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-19-25 08:00AM	Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-07-25 05:13PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.07%
Jan-13-25 08:00AM	Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts (PR Newswire)
Jan-03-25 05:20PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-18-24 08:00AM	Spyre Therapeutics Added to the Nasdaq Biotechnology Index (PR Newswire) -8.31%
Dec-02-24 05:03PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
08:00AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies (PR Newswire)
Nov-25-24 05:11PM	Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-18-24 09:18PM	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) -6.17%
04:14PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (PR Newswire)
Nov-12-24 07:30AM	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing (PR Newswire) -8.97%
Nov-11-24 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 (PR Newswire)
04:05PM	Loading…
Nov-07-24 04:05PM	Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +5.00%
Nov-01-24 04:44PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Oct-30-24 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (PR Newswire)
Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)
Dec-07-23 06:20PM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire)
Nov-28-23 08:00AM	Spyre Therapeutics to Present at Upcoming Investor Conference (PR Newswire) +20.73%
Nov-27-23 08:30AM	Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD (PR Newswire) +8.79%
Nov-22-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) +6.26%
Nov-09-23 06:26PM	Aeglea: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) -5.39%
Oct-30-23 08:00PM	Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences (PR Newswire) +9.57%
Oct-02-23 06:02PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire)
Sep-14-23 05:03PM	Aeglea BioTherapeutics to Participate in Upcoming September Conference (PR Newswire) -6.63%
Sep-07-23 08:40AM	Aeglea BioTherapeutics Announces Reverse Stock Split (PR Newswire)
Sep-05-23 07:00AM	Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones (PR Newswire)
Aug-11-23 07:07AM	Aeglea: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-27-23 07:00AM	Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma (PR Newswire)
Jun-23-23 04:30PM	Aeglea BioTherapeutics Announces Grant of Inducement Awards (PR Newswire) -12.30% -5.30%
10:31AM	Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics (Zacks)
Jun-22-23 10:59AM	Aeglea BioTherapeutics Stock Surges Over 400% Today - What's Going On (Benzinga) +328.67%
08:17AM	Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics (PR Newswire)
May-13-23 08:03AM	Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:15AM	Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Aeglea: Q1 Earnings Snapshot (AP Finance)
07:01AM	Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-13-23 09:44AM	Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails (Zacks) -7.37%
Apr-12-23 07:00AM	Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives (PR Newswire) -26.21%
Mar-17-23 05:30PM	Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.35%
Mar-02-23 10:15AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates (PR Newswire)
Feb-12-23 07:40AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 months (Simply Wall St.)
Jan-06-23 07:01AM	Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency (PR Newswire)
Jan-02-23 07:29AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Dec-14-22 12:00PM	Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-02-22 04:05PM	Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +18.17% -5.90%
Nov-30-22 10:38AM	Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease (Benzinga) -65.98%
07:01AM	Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer (PR Newswire)
Nov-15-22 04:25PM	Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer (PR Newswire) -5.88%
Nov-03-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.56%
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Oct-21-22 12:27PM	Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers (Zacks) +6.02%
12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-19-22 04:05PM	Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment (PR Newswire)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burrows Scott L	Chief Financial Officer	Sep 02 '25	Sale	16.26	18,428	299,639	97,994	Sep 03 06:53 PM
Albers Jeffrey W.	Director	Nov 06 '24	Sale	36.76	6,700	246,313	27,360	Nov 08 04:53 PM
Albers Jeffrey W.	Director	Oct 25 '24	Sale	36.43	300	10,929	34,060	Oct 28 04:41 PM
SESSIONS, LLC	Director	Oct 25 '24	Proposed Sale	33.70	7,000	235,900		Oct 25 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SYRE

Spyre Therapeutics Inc

Upgrade your FINVIZ experience